These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Rescue of dystrophin mRNA of Duchenne muscular dystrophy by inducing exon skipping. Matsuo M; Takeshima Y Acta Myol; 2005 Oct; 24(2):110-4. PubMed ID: 16550927 [TBL] [Abstract][Full Text] [Related]
31. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822 [TBL] [Abstract][Full Text] [Related]
32. Duchenne and Becker muscular dystrophy: from gene diagnosis to molecular therapy. Matsuo M IUBMB Life; 2002 Mar; 53(3):147-52. PubMed ID: 12102170 [TBL] [Abstract][Full Text] [Related]
33. From gRNA Identification to the Restoration of Dystrophin Expression: A Dystrophin Gene Correction Strategy for Duchenne Muscular Dystrophy Mutations Using the CRISPR-Induced Deletion Method. Duchêne B; Iyombe-Engembe JP; Rousseau J; Tremblay JP; Ouellet DL Methods Mol Biol; 2018; 1687():267-283. PubMed ID: 29067670 [TBL] [Abstract][Full Text] [Related]
34. Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45. Findlay AR; Wein N; Kaminoh Y; Taylor LE; Dunn DM; Mendell JR; King WM; Pestronk A; Florence JM; Mathews KD; Finkel RS; Swoboda KJ; Howard MT; Day JW; McDonald C; Nicolas A; Le Rumeur E; Weiss RB; Flanigan KM; Ann Neurol; 2015 Apr; 77(4):668-74. PubMed ID: 25612243 [TBL] [Abstract][Full Text] [Related]
35. Less is more: therapeutic exon skipping for Duchenne muscular dystrophy. Aartsma-Rus A; van Ommen GJ Lancet Neurol; 2009 Oct; 8(10):873-5. PubMed ID: 19713153 [No Abstract] [Full Text] [Related]
36. [Effective exon skipping in humans: a symbolic but promising jump into DMD therapy]. Kaplan JC; Chelly J; Garcia L Med Sci (Paris); 2008 Feb; 24(2):215-7. PubMed ID: 18272087 [No Abstract] [Full Text] [Related]
37. Exon skipping therapy for Duchenne muscular dystrophy. Kole R; Krieg AM Adv Drug Deliv Rev; 2015 Jun; 87():104-7. PubMed ID: 25980936 [TBL] [Abstract][Full Text] [Related]
38. Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies. Toh ZY; Thandar Aung-Htut M; Pinniger G; Adams AM; Krishnaswarmy S; Wong BL; Fletcher S; Wilton SD PLoS One; 2016; 11(1):e0145620. PubMed ID: 26745801 [TBL] [Abstract][Full Text] [Related]
39. Eteplirsen in the treatment of Duchenne muscular dystrophy. Lim KR; Maruyama R; Yokota T Drug Des Devel Ther; 2017; 11():533-545. PubMed ID: 28280301 [TBL] [Abstract][Full Text] [Related]
40. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]